[Open study of befuraline (DIV 154) in 64 depressive patients (author's transl)].

Abstract

The therapeutic efficacy of the new compound N-benzo[B]-furan-2-ylcarbonyl-N'-benzylpiperazine hydrochloride (befuraline) was evaluated in 64 patients presenting various depressive syndromes. Improvement was found in 33 cases (= 52%) under a daily dose of 150 mg befuraline; 31 of these patients improved within the first 8 days of treatment. Patients with endogenous depression responded favourably to the befuraline therapy, 23 (= 70%) of these (33) patients showing full recovery. Improvement was more frequently observed in patients with mild depression than in severe cases. It seems noteworthy that under befuraline treatment there was also a marked improvement in 21 cases in whom previous long-term therapy with other psychotropic drugs had remained ineffective. Side effects consisted mainly of reversible psycho-organic troubles; extrapyramidal disorders were not observed.

• Authors: R Clemens, U Clemens
• Journal: Arzneimittel-Forschung (Arzneimittelforschung) Vol. 27 Issue 12 Pg. 2416-21 ( 1977) ISSN: 0004-4172 [Print] Germany
• Vernacular Title: Offener Versuch mit Befuraline (DIV 154) bei 64 depressiv Kranken.
• PMID: 341906 (Publication Type: Clinical Trial, Comparative Study, Journal Article)

Chemical References

• Antidepressive Agents
• Benzofurans
• Piperazines
• Placebos
• befuraline

Topics

• Adult
• Aged
• Antidepressive Agents
• Benzofurans (therapeutic use)
• Clinical Trials as Topic
• Depression (complications, drug therapy)
• Double-Blind Method
• Female
• Humans
• Male
• Middle Aged
• Piperazines (therapeutic use)
• Placebos